EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSLCRG00005004040
Gene Symbol: MAP3K8
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSLCRG00005021780
Gene Symbol: MAP3K9
3 Cross references
193 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSLCRG00005012466
Gene Symbol: MGLL
3 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSLCRG00005016891
Gene Symbol: MLNR
3 Cross references
174 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2

Ensembl ID : ENSLCRG00005018246
Gene Symbol: LOC104940443
2 Cross references
185 Possible Orthologues:

Natriuretic Peptide Receptor 1a

Ensembl ID : ENSLCRG00005010103
Gene Symbol: NPR1A
2 Cross references
190 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSLCRG00005004321
Gene Symbol: NPR2
3 Cross references
191 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSLCRG00005019103
Gene Symbol: NPR3
3 Cross references
211 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1

Ensembl ID : ENSLCRG00005019890
Gene Symbol: LOC104923664
3 Cross references
201 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-2

Ensembl ID : ENSLCRG00005015422
Gene Symbol: LOC104929159
3 Cross references
193 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7

Ensembl ID : ENSLCRG00005010149
Gene Symbol: LOC104920497
3 Cross references
205 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSLCRG00005017700
Gene Symbol: NPY2R
3 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).